Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase III clinical trial programme for KD 019

Trial Profile

Phase III clinical trial programme for KD 019

Phase of Trial: Phase III

Latest Information Update: 13 Nov 2007

At a glance

  • Drugs Tesevatinib (Primary)
  • Indications Cancer
  • Focus Registrational; Therapeutic Use
  • Sponsors Exelixis
  • Most Recent Events

    • 13 Nov 2007 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top